Anti-FAM13A Polyclonal Antibody for WB, ELISA - O94988

Core Product Specifications and Parameters

Biological Background: FAM13A Function and Localization

• FAM13A (also known as FAM13A1 or ARHGAP48) is encoded by the FAM13A gene.
• It contains a coiled coil domain and a Rho GTPase-activating protein (RhoGAP) domain, suggesting a role in modulating small GTPase signaling.
• Alternative splicing generates multiple isoforms; isoform 1 is widely expressed with highest levels in skeletal muscle, thymus, brain, and lung, while isoform 3 is predominant in kidney, pancreas, liver, lung, and thymus.
• Post-translational modifications include phosphorylation (Phosphoprotein keyword), indicating potential regulation by kinases.
• The protein is identified in proteomics studies, supporting its expression in various tissues.
• The predicted molecular weight is approximately 117 kDa.
• Additional research is needed to fully elucidate its subcellular localization and specific cellular functions.

Experimental Guidance and Technical Tips

• The immunogen comprises the N-terminal region (aa 1-200) of human FAM13A; consider verifying reactivity against full-length protein in WB.
• For WB, target a band around 117 kDa; loading controls at distinct molecular weights may reduce interference.
• Assay conditions (antibody dilution, blocking, incubation times) should be optimized for each experimental system.
• For ELISA, a direct or indirect format can be employed; pairing with a detection antibody requires independent validation.
• Cross-reactivity with other species has not been tested; validate if used beyond human samples.

CamelBio: Your One-Stop Sourcing Bridge

At CamelBio, we streamline your IVD raw material procurement with a comprehensive portfolio that includes validated antibody pairs, monoclonal and polyclonal antibodies, and bulk ancillary reagents. This FAM13A antibody supports GTPase signaling and alternative splicing research, complementing our expertise in sourcing high-quality reagents for emerging targets. Partner with us for end-to-end support from concept to clinic.